JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Harvard Bioscience Inc

Gesloten

SectorGezondheidszorg

0.47 -9.62

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.42

Max

0.53

Belangrijke statistieken

By Trading Economics

Inkomsten

-50M

-50M

Verkoop

-2.8M

22M

Winstmarge

-231.193

Werknemers

330

EBITDA

-43M

-40M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+264.58% upside

Dividenden

By Dow Jones

Volgende Winsten

6 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3.7M

19M

Vorige openingsprijs

10.09

Vorige sluitingsprijs

0.47

Nieuwssentiment

By Acuity

37%

63%

119 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Harvard Bioscience Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 aug 2025, 17:49 UTC

Belangrijke Marktbewegers

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 aug 2025, 17:18 UTC

Belangrijke Marktbewegers

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 aug 2025, 16:25 UTC

Winsten

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 aug 2025, 23:50 UTC

Marktinformatie

Nikkei May Rise as Yen Weakens -- Market Talk

11 aug 2025, 23:42 UTC

Marktinformatie

Global Energy Roundup: Market Talk

11 aug 2025, 23:42 UTC

Marktinformatie

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 aug 2025, 23:36 UTC

Marktinformatie

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 aug 2025, 23:32 UTC

Marktinformatie

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 aug 2025, 23:02 UTC

Marktinformatie

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 aug 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

11 aug 2025, 20:37 UTC

Winsten
Acquisities, Fusies, Overnames

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 aug 2025, 20:37 UTC

Winsten
Acquisities, Fusies, Overnames

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 aug 2025, 20:37 UTC

Winsten
Acquisities, Fusies, Overnames

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement 2Q Rev $25.8M >EXOD

11 aug 2025, 20:14 UTC

Marktinformatie

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 aug 2025, 19:12 UTC

Marktinformatie

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 aug 2025, 18:56 UTC

Marktinformatie

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 aug 2025, 18:31 UTC

Marktinformatie

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 aug 2025, 17:43 UTC

Marktinformatie

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 aug 2025, 17:28 UTC

Marktinformatie

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 aug 2025, 17:16 UTC

Marktinformatie

Commodity Longs Fall to 11-Month Low -- Market Talk

11 aug 2025, 16:42 UTC

Acquisities, Fusies, Overnames

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 aug 2025, 16:27 UTC

Acquisities, Fusies, Overnames

BBVA Says Sabadell Offer Remains in Effect

11 aug 2025, 16:26 UTC

Acquisities, Fusies, Overnames

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 aug 2025, 16:25 UTC

Acquisities, Fusies, Overnames

Banco de Sabadell Announced TSB Sale on July 1

11 aug 2025, 16:25 UTC

Acquisities, Fusies, Overnames

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Peer Vergelijking

Prijswijziging

Harvard Bioscience Inc Prognose

Koersdoel

By TipRanks

264.58% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1.75 USD  264.58%

Hoogste 3 USD

Laagste 0.5 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Harvard Bioscience Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Technische score

By Trading Central

0.3 / 0.3401Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

No Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

119 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.